The Recall Desk

Hazard

Allergen Exposure recalls

168 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
168
Critical
0
Severe
148
Most recent
2016-07-27

Of the 168 allergen exposure recalls we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 148 (88%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergen exposure recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

76–100 of 168

  • SevereFDA (Drugs)·D-901-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sodium Starch Glycolate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sodium Starch Glycolate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Sodium Starch Glycolate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-580-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloroxine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloroxine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloroxine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-678-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flucytosine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flucytosine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flucytosine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-697-2015·2015-04-29

    Attix Pharmaceuticals Recalls Gatifloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Gatifloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Gatifloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-885-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ropivacaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ropivacaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ropivacaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-676-2015·2015-04-29

    Attix Pharmaceuticals Recalls Floxuridine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Floxuridine active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Floxuridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-910-2015·2015-04-29

    Tacrolimus Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Tacrolimus Monohydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tacrolimus Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-512-2015·2015-04-29

    Amiloride HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Amiloride HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Amiloride HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-637-2015·2015-04-29

    Attix Pharmaceuticals Recalls Domperidone API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Domperidone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Domperidone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-526-2015·2015-04-29

    Atazanavir API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Atazanavir active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Atazanavir active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-584-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cidofovir Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cidofovir Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cidofovir Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-527-2015·2015-04-29

    Attix Pharmaceuticals Recalls Atomoxetine HCl Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Atomoxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Atomoxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-918-2015·2015-04-29

    Attix Pharmaceuticals Recalls Temozolomide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Temozolomide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Temozolomide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-595-2015·2015-04-29

    Attix Pharmaceuticals Recalls Clomipramine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Clomipramine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Clomipramine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-692-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formoterol Fumarate Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formoterol Fumarate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Formoterol Fumarate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-605-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cyclobenzaprine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Cyclobenzaprine HCI repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination.

    Product
    Cyclobenzaprine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-912-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tadalafil Citrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tadalafil Citrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tadalafil Citrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-513-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aminocaproic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Aminocaproic Acid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Aminocaproic Acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-787-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methscopolamine Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methscopolamine Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methscopolamine Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-765-2015·2015-04-29

    Attix Pharmaceuticals Recalls Liothyronine Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Liothyronine Sodium (T3) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Liothyronine Sodium (T3) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-770-2015·2015-04-29

    Losartan Potassium Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Losartan Potassium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Losartan Potassium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-563-2015·2015-04-29

    Attix Pharmaceuticals Recalls Carboxymethyl Cellulose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Carboxymethyl Cellulose Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Carboxymethyl Cellulose Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-505-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bovine Albumin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Bovine Albumin repackaged between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Albumin (Bovine) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-634-2015·2015-04-29

    Attix Pharmaceuticals Recalls Disulfiram API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Disulfiram active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Disulfiram active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-749-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lanthanum Carbonate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Lanthanum Carbonate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lanthanum Carbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide